bd@krishbiotech.com +91 33 2582-4472

Research Portfolios

An overview:

  • KBRPL has expanded their horizons by initiating the drug discovery efforts in areas that have scientific and commercial promise: Metabolic Disorders, Oncology,Immunology, Pain and Inflammation.
  • The research model would focus both on acquiring new assets from other organizations /Institutes as well as out-licensing existing in-house portfolios.
  • KBRPL in-licensed two programs from Piramal Enterprises Ltd., Mumbai, namely RoR-gamma t antagonist (for autoimmune disorders) and GPR120 agonists (for diabetes and metabolic disorders).
  • The state-of-the art, R & D centre is situated in Kalyani, a well-connected town on the outskirts of Kolkata.
  • KBRPL has 5 molecules in various stages of discovery to preclinical development
  • Several collaborative research programs have been signed with premier government institutes like Indian Institute of Technology, Roorkee, National Institute of Technology, Durgapur etc.

 

Inflammation and Immunology

Molecule        KBRPL1001

Target RoR-gt
Indication Autoimmune and inflammatory disorders
Highest stage Preclinical development

Diabetes and Metabolic disorders

Molecule        KBRPL2001

Target GPR120
Indication Diabetes and metabolic disorders
Highest stage Preclinical development
Highlights First in class to have shown preclinical proof of concept in a chronic efficacy DIO mouse model

Oncology

Molecule        KBRPL3001

Target Undisclosed
Highest stage Discovery

Molecule        KBRPL3002

Target Undisclosed
Highest stage Discovery

Pain

Molecule        KBR4001

Target Undisclosed
Highest stage Discovery
  • 
Download Brochure
  • Career
  • Feedback
T-1, QK-17 (Part) WBIIDC, Phase III,
Kalyani, Nadia, West Bengal 741 235 ,INDIA

+91 33 2582-4472